Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France

Oral Communications

Cushing's and acromegaly

ea0063oc3.1 | Cushing's and acromegaly | ECE2019

Osilodrostat provides clinical benefit over 48 weeks in patients with Cushing disease: Results from the LINC 3 study

Pivonello Rosario , Fleseriu Maria , Newell-Price John , Bertagna Xavier , Findling James , Shimatsu Akira , Gu Feng , Auchus Richard , Leelawattana Rattana , Jig Lee Eun , Hee Kim Jung , Lacroix Andre , Laplanche Audrey , O'Connell Paul , M Pedroncelli Alberto , Tauchmanova Libuse , MK Biller Beverly

Introduction: Osilodrosat is a potent oral 11β-hydroxylase inhibitor. During the 24-week, single-arm, open-label period of the Phase III LINC 3 study (NCT02180217), osilodrostat treatment demonstrated rapid, sustained reduction in mean urinary free cortisol (mUFC) in most Cushing disease (CD) patients. In the subsequent 8-week, double-blind, randomized-withdrawal phase, a significantly higher proportion of patients receiving osilodrostat maintained normal mUFC at week (W)...

ea0063oc3.2 | Cushing's and acromegaly | ECE2019

Outcomes after primary treatment for Nelson’s syndrome: a study from 13 UK centres

Fountas Athanasios , Lim Eugenie , Drake William M , Polson Andrew , Gurnell Mark , Martin Niamh M , Seejore Khyatisha , Murray Robert D , MacFarlane James , Ahluwalia Rupa , Swords Francesca , Ashraf Muhammad , Pal Aparna , Chong Zhuomin , Freel Marie , Balafshan Tala , Purewal Tejpal S , Speak Rowena G , Newell-Price John , Higham Claire , Hussein Ziad , Baldeweg Stephanie E , Dales Jolyon , Reddy Narendra , Levy Miles , Karavitaki Niki

Nelson’s syndrome (NS) is a potentially severe complication following bilateral adrenalectomy for Cushing’s disease (CD). Series assessing outcomes of treatments for NS are limited by small sample size, often short follow-up and variability of success criteria. We performed a UK multi-centre study aiming to review outcomes of primary treatment for NS. Clinical, laboratory, imaging data were collected. Kaplan-Meier method, log-rank test, Cox regression analysis were u...

ea0063oc3.3 | Cushing's and acromegaly | ECE2019

Monosynaptic inputs to corticotropin-releasing hormone neuron in hypothalamic paraventricular nucleus of mice at the whole brain scale

Wang Yu , Zhou Jiang-Ning

Corticotropin-releasing hormone (CRH), a 41-aminoacid peptide that is mainly produced in the hypothalamic paraventricular nucleus (PVN), plays a crucial role in stress response and is considered to be the central driving force in the activity of hypothalamic–pituitary–adrenal (HPA) axis. Previous studies of neuronal input to the PVN were limited by experimental techniques and could not be restricted by a single neuron type. In the present study, by using a novel defi...

ea0063oc3.4 | Cushing's and acromegaly | ECE2019

Restoration of basal glucose turnover after disease control in acromegaly depends on treatment modality: a prospective, investigator-initiated trial

Arlien-Soborg Mai C , Dal Jakob , Madsen Michael , Hogild Morten , Hjelholt Astrid , Jessen Niels , Moller Niels , Otto Lunde Jorgensen Jens

Background: Growth Hormone (GH) reversibly suppresses insulin-stimulated glucose uptake in skeletal muscle, but less is known about GH effects on glucose metabolism in the basal state. Somatostatin suppresses GH as well as insulin, and may also exert direct effects in skeletal muscle. This may have therapeutic implications in the treatment of acromegalic patients with a somatostatin analogue (SA).Aim: To study basal and insulin-stimulated glucose metabol...

ea0063oc3.5 | Cushing's and acromegaly | ECE2019

T2-signal intensity, SST receptor expression and first-generation somatostatin analogues efficacy predict hormone and tumor responses to pasireotide in acromegaly

Coopmans Eva C , Schneiders Joppe J , El-Sayed Nour , Muhammad Ammar , Hofland Leo J , Petrossians Patrick , van der Lely Aart. J , JCMM Neggers Sebastian

Background: Previous studies indicate that PAS-LAR can achieve control of insulin-like growth factor I (IGF-I) levels and may reduce tumor size, however a subset of acromegaly patients responds poorly. T2-signal intensity, somatostatin receptor (SST) subtype 2 and 5 expression, and the response to first-generation somatostatin receptor ligands (SRLs) are recognized predictors of therapy response. Valid prediction of the response to PAS-LAR can alter treatment stratification.</...